TY - JOUR
T1 - Recurrence in Plasmodium vivax malaria
T2 - a prospective cohort study with long follow-up from a coastal region in South-West India
AU - Gandrala, Divya
AU - Gupta, Nitin
AU - Lavu, Alekhya
AU - Nallapati, Vishnu Teja
AU - Guddattu, Vasudeva
AU - Saravu, Kavitha
N1 - Publisher Copyright:
Copyright: © 2022 Gandrala D et al.
PY - 2022
Y1 - 2022
N2 - Background: India is endemic for Plasmodium vivax(Pv) malaria. Despite a decrease in incidence, its elimination is hampered by recurrences. This study aimed to characterize recurrences in Pv malaria and study its association with primaquine (PQ) usage. Methods: Symptomatic adult Pv patients were followed-up for up to 23 months for recurrences. The time to recurrence was compared by the PQ dosage they received using a log-rank test. Results: Of the 294 malaria patients, 206 (70%) patients had Pv infection during the study period. A total of 20 (9.7%) recurrences were seen in 17 (8.2%) patients of Pv. The percentage of first-time recurrences were highest in the no PQ group (25%), followed by the weekly PQ group (20%), low dose daily PQ (8.2%) group, and high dose daily PQ group (3.1%). Conclusions: Recurrence in Pv malaria is common, especially in those who receive an inappropriate prescription of primaquine.
AB - Background: India is endemic for Plasmodium vivax(Pv) malaria. Despite a decrease in incidence, its elimination is hampered by recurrences. This study aimed to characterize recurrences in Pv malaria and study its association with primaquine (PQ) usage. Methods: Symptomatic adult Pv patients were followed-up for up to 23 months for recurrences. The time to recurrence was compared by the PQ dosage they received using a log-rank test. Results: Of the 294 malaria patients, 206 (70%) patients had Pv infection during the study period. A total of 20 (9.7%) recurrences were seen in 17 (8.2%) patients of Pv. The percentage of first-time recurrences were highest in the no PQ group (25%), followed by the weekly PQ group (20%), low dose daily PQ (8.2%) group, and high dose daily PQ group (3.1%). Conclusions: Recurrence in Pv malaria is common, especially in those who receive an inappropriate prescription of primaquine.
UR - http://www.scopus.com/inward/record.url?scp=85128802559&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85128802559&partnerID=8YFLogxK
U2 - 10.12688/f1000research.109577.1
DO - 10.12688/f1000research.109577.1
M3 - Article
C2 - 35464047
AN - SCOPUS:85128802559
SN - 2046-1402
VL - 11
SP - 279
JO - F1000Research
JF - F1000Research
ER -
